Patents by Inventor C. Frank Bennett

C. Frank Bennett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9506062
    Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: November 29, 2016
    Assignees: Regulus Therapeutics Inc., Rosetta Genomics Ltd.
    Inventors: C. Frank Bennett, Ayelet Chajut, Christine Esau, Eric Marcusson, Noga Yerushalmi
  • Publication number: 20160312217
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.
    Type: Application
    Filed: January 25, 2016
    Publication date: October 27, 2016
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
  • Patent number: 9476051
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of superoxide dismutase 1, soluble. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding superoxide dismutase 1, soluble. Methods of using these compounds for modulation of superoxide dismutase 1, soluble expression and for treatment of diseases associated with expression of superoxide dismutase 1, soluble are provided.
    Type: Grant
    Filed: February 24, 2015
    Date of Patent: October 25, 2016
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Kenneth W. Dobie, Susan M. Freier, Thomas P. Condon, Ravi Jain, Richard Alan Smith, Don W. Cleveland
  • Publication number: 20160304877
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preferentially reducing CUGexp DMPK RNA, reducing myotonia or reducing spliceopathy in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate type 1 myotonic dystrophy, or a symptom thereof.
    Type: Application
    Filed: August 11, 2014
    Publication date: October 20, 2016
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Sanjay K. Pandey, Robert A. MacLeod, C. Frank Bennett, Susan M. Freier
  • Patent number: 9447412
    Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
    Type: Grant
    Filed: August 28, 2013
    Date of Patent: September 20, 2016
    Assignee: Regulus Therapeutics Inc.
    Inventors: Bridget Gordon, C. Frank Bennett, Susan M. Freier, Richard H. Griffey, Eric E. Swayze, Ravi Jain, Balkrishen Bhat
  • Patent number: 9447413
    Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
    Type: Grant
    Filed: May 4, 2015
    Date of Patent: September 20, 2016
    Assignee: Regulus Therapeutics Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Richard H. Griffey
  • Publication number: 20160237432
    Abstract: Disclosed herein are methods for reducing expression of C90RF72 antisense transcript in an animal with C90RF72 antisense transcript specific inhibitors. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Such C90RF72 antisense transcript specific inhibitors include antisense compounds.
    Type: Application
    Filed: October 14, 2014
    Publication date: August 18, 2016
    Applicants: Ionis Pharmaceuticals, Inc., The Regents of the University of California, Ludwig Institute For Cancer Research
    Inventors: C. Frank Bennett, Frank Rigo, Don W. Cleveland, Clotilde Lagier-Tourenne, John M. Ravits, Michael W. Baughn
  • Publication number: 20160194637
    Abstract: The present invention provides compounds and methods for modulating target nucleic acids found in organelles or sub-organelles of cells. The invention includes, but is not limited to compounds and methods that modulate target nucleic acids in a sub-nuclear organelle, such as the nucleolus and/or a cajal body. In certain embodiments, the cell is in an animal.
    Type: Application
    Filed: March 4, 2016
    Publication date: July 7, 2016
    Applicants: Ionis Pharmaceuticals, Inc., Cold Spring Harbor Laboratory
    Inventors: Xue-hai Liang, Stanley T. Crooke, C. Frank Bennett, David L. Spector
  • Patent number: 9353371
    Abstract: The present invention provides compounds comprising oligonucleotides complementary to an Usher transcript. Certain such compounds are useful for hybridizing to an Usher transcript, including but not limited, to an Usher transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the Usher transcript. In certain such embodiments, the Usher transcript includes a mutation that results in cryptic splicing and hybridization of the oligonucleotide results in a decrease in the amount of cryptic splicing. In certain embodiments, such compounds are used to treat Usher Syndrome.
    Type: Grant
    Filed: May 2, 2012
    Date of Patent: May 31, 2016
    Assignees: Ionis Pharmaceuticals, Inc., Rosalind Franklin University of Medicine and Science
    Inventors: Michelle L. Hastings, Frank Rigo, C. Frank Bennett
  • Publication number: 20160068845
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preferentially reducing CUGexp DMPK RNA, reducing myotonia or reducing spliceopathy in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate type 1 myotonic dystrophy, or a symptom thereof.
    Type: Application
    Filed: July 30, 2015
    Publication date: March 10, 2016
    Applicants: UNIVERSITY OF ROCHESTER, ISIS PHARMACEUTICALS, INC.
    Inventors: C. Frank Bennett, Susan M. Freier, Robert A. MacLeod, Sanjay K. Pandey, Charles A. Thornton, Thurman Wheeler, Seng H. Cheng, Andrew Leger, Bruce M. Wentworth
  • Patent number: 9273315
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: March 1, 2016
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
  • Publication number: 20160053256
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's disease progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntingtin's disease in an individual susceptible to Huntingtin's Disease. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.
    Type: Application
    Filed: May 11, 2015
    Publication date: February 25, 2016
    Applicants: CHDI FOUNDATION INC., ISIS PHARMACEUTICALS, INC.
    Inventors: Gene Hung, C. Frank Bennett, Janet M. Leeds, Susan M. Freier
  • Patent number: 9267138
    Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
    Type: Grant
    Filed: May 6, 2015
    Date of Patent: February 23, 2016
    Assignee: Regulus Therapeutics Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Richard H. Griffey
  • Publication number: 20160046941
    Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.
    Type: Application
    Filed: August 24, 2015
    Publication date: February 18, 2016
    Inventors: C. Frank Bennett, Ayelet Chajut, Christine Esau, Eric Marcusson, Noga Yerushalmi
  • Publication number: 20160032285
    Abstract: Disclosed are methods for modulating splicing of Tau mRNA in an animal with Tau antisense compounds. Also disclosed herein are methods for reducing expression of Tau mRNA and protein in an animal with Tau antisense compounds. Such compounds and methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration Tau antisense oligonucleotides include Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy, Chronic Traumatic Encephalopathy, Epilepsy, and Dravet's Syndrome.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 4, 2016
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Frank Rigo, C. Frank Bennett
  • Publication number: 20160024496
    Abstract: Disclosed herein are methods for monitoring expression of C9ORF72 mRNA and protein in an animal with C9ORF72 specific inhibitors. Such C9ORF72 specific inhibitors include antisense compounds.
    Type: Application
    Filed: October 15, 2013
    Publication date: January 28, 2016
    Applicants: The Johns Hopkins University, Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Jeffrey D. Rothstein, Christopher Donnelly, Rita G. Sattler
  • Publication number: 20160017329
    Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
    Type: Application
    Filed: July 21, 2015
    Publication date: January 21, 2016
    Inventors: Christine Esau, Bridget Lollo, C. Frank Bennett, Susan M. Freier, Richard H. Griffey, Brenda F. Baker, Timothy A. Vickers, Eric G. Marcusson, Erich Koller, Eric E. Swayze, Ravi Jain, Balkrishen Bhat, Eigen Peralta
  • Publication number: 20160010086
    Abstract: The present invention provides method of optimizing the efficacy and potency of antisense compounds. In certain embodiments, the invention provides assays useful for determining favorable oligonucleotide characteristics and excipients for improved cellular uptake.
    Type: Application
    Filed: December 2, 2014
    Publication date: January 14, 2016
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: C. FRANK BENNETT, RICHARD S. GEARY, ERIC E. SWAYZE, ANDREW M. SIWKOWSKI
  • Publication number: 20160002627
    Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.
    Type: Application
    Filed: January 9, 2014
    Publication date: January 7, 2016
    Applicant: Isis Pharmaceuticals. Inc.
    Inventors: C. Frank Bennett, Gene Hung, Frank Rigo
  • Publication number: 20150376623
    Abstract: This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds.
    Type: Application
    Filed: June 29, 2015
    Publication date: December 31, 2015
    Applicants: EXCALIARD PHARMACEUTICALS, INC., ISIS PHARMACEUTICALS, INC.
    Inventors: Nicholas M. Dean, J. Gordon Foulkes, Niall O'Donnell, C. Frank Bennett, Susan M. Freier